In this regard, our results demonstrated that both SB and SP treatments at higher doses significantly reduced E-cadherin expression, suggesting that SB and SP could alleviate the symptoms of migraine associated with intestinal-barrier alteration; additionally, the effects of SB and SP on intestinal permeability are confirmed also by FITC–Dextran assay. Here, CDH1 is linked to migraine disorder.